Biological Breast Cancer Classification by qRT-PCR View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2005-2012

FUNDING AMOUNT

8695563 USD

ABSTRACT

DESCRIPTION (provided by applicant): Breast cancer is a difficult disease to manage because it is comprised of a wide spectrum of tumor subtypes with different biological characteristics, therapeutic responses and clinical outcomes. A biomarker-based classification of breast cancer that effectively matches intrinsic biological characteristics with the most effective therapeutic protocol would be a significant advance. Gene expression analysis using a breast tumor "intrinsic" gene set has reproducibly identified five distinct subtypes of breast tumors: Luminal A (LumA), Luminal B (LumB), Normal Breast-like (NB), HER2-positive (HER2+) and Basal-like. Each subtype has a distinct biology and clinical behavior and evidence suggests that each has a unique drug sensitivity pattern. We have also shown that this classification identifies prognostic groups that are reproducible across different patient populations and are independent of standard clinical parameters. RNA expression profiling is the most robust and reproducible way to identify these biological subtypes and we believe that our proposed classification can be accomplished in an automated fashion without subjective interpretation. In order to generalize the clinical significance of these findings to larger populations we will develop an assay to allow classification from formalin-fixed, paraffin-embedded (FFPE) tissues so that RNA from aged blocks can be accurately profiled. Next, we will retrospectively validate our "intrinsic" gene set on uniformly treated cohorts of thousands of patients. Our goal is to develop a clinical test for these five subtypes using expression analysis by real-time quantitative RT-PCR. With the additional information that we expect to gain by profiling clinical samples from homogeneously treated patients and patients subjected to treatment randomization, we will be able to provide valuable prognostic information for patients with node negative breast cancer and predictive information for the efficacy of chemotherapy regimens for patients with node positive disease. It is our long term goal to develop a broadly applicable subtyping test for all early stage breast cancer patients. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=7658284

Related SciGraph Publications

  • 2018-02. Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up in BREAST CANCER RESEARCH AND TREATMENT
  • 2016-12. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) in NPJ BREAST CANCER
  • 2016-08-09. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers in NATURE COMMUNICATIONS
  • 2015-12. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay in BMC MEDICAL GENOMICS
  • 2014-10. Predicting response and survival in chemotherapy-treated triple-negative breast cancer in BRITISH JOURNAL OF CANCER
  • 2014-10. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration in BREAST CANCER RESEARCH
  • 2013-11. A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard in MODERN PATHOLOGY
  • 2013-04. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2013-01. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-12. PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers in BMC MEDICAL GENOMICS
  • 2012-06. Whole-genome analysis informs breast cancer response to aromatase inhibition in NATURE
  • 2012-04. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer in BREAST CANCER RESEARCH
  • 2010-09. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool in BRITISH JOURNAL OF CANCER
  • 2010-04-15. Genome remodelling in a basal-like breast cancer metastasis and xenograft in NATURE
  • 2010-01. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients in BREAST CANCER RESEARCH AND TREATMENT
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "amount": {
          "currency": "USD", 
          "type": "MonetaryAmount", 
          "value": "8695563"
        }, 
        "description": "DESCRIPTION (provided by applicant): Breast cancer is a difficult disease to manage because it is comprised of a wide spectrum of tumor subtypes with different biological characteristics, therapeutic responses and clinical outcomes. A biomarker-based classification of breast cancer that effectively matches intrinsic biological characteristics with the most effective therapeutic protocol would be a significant advance. Gene expression analysis using a breast tumor \"intrinsic\" gene set has reproducibly identified five distinct subtypes of breast tumors: Luminal A (LumA), Luminal B (LumB), Normal Breast-like (NB), HER2-positive (HER2+) and Basal-like. Each subtype has a distinct biology and clinical behavior and evidence suggests that each has a unique drug sensitivity pattern. We have also shown that this classification identifies prognostic groups that are reproducible across different patient populations and are independent of standard clinical parameters. RNA expression profiling is the most robust and reproducible way to identify these biological subtypes and we believe that our proposed classification can be accomplished in an automated fashion without subjective interpretation. In order to generalize the clinical significance of these findings to larger populations we will develop an assay to allow classification from formalin-fixed, paraffin-embedded (FFPE) tissues so that RNA from aged blocks can be accurately profiled. Next, we will retrospectively validate our \"intrinsic\" gene set on uniformly treated cohorts of thousands of patients. Our goal is to develop a clinical test for these five subtypes using expression analysis by real-time quantitative RT-PCR. With the additional information that we expect to gain by profiling clinical samples from homogeneously treated patients and patients subjected to treatment randomization, we will be able to provide valuable prognostic information for patients with node negative breast cancer and predictive information for the efficacy of chemotherapy regimens for patients with node positive disease. It is our long term goal to develop a broadly applicable subtyping test for all early stage breast cancer patients.", 
        "endDate": "2012-05-31T00:00:00Z", 
        "funder": {
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "type": "Organization"
        }, 
        "id": "sg:grant.2689066", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "2689066"
            ]
          }, 
          {
            "name": "nih_id", 
            "type": "PropertyValue", 
            "value": [
              "U01CA114722"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "different biological characteristics", 
          "breast cancer", 
          "FFPE", 
          "biological subtypes", 
          "subjective interpretation", 
          "genes", 
          "clinical tests", 
          "standard clinical parameters", 
          "HER2+", 
          "luminal A", 
          "negative breast cancer", 
          "formalin", 
          "additional information", 
          "intrinsic biological characteristics", 
          "description", 
          "qRT-PCR", 
          "basal", 
          "treatment randomization", 
          "block", 
          "clinical significance", 
          "assay", 
          "clinical outcomes", 
          "effective therapeutic protocols", 
          "different patient populations", 
          "applicants", 
          "automated fashion", 
          "long term goal", 
          "breast tumors", 
          "biomarkers", 
          "findings", 
          "valuable prognostic information", 
          "RNA expression", 
          "chemotherapy regimens", 
          "patients", 
          "distinct subtypes", 
          "Biological Breast Cancer Classification", 
          "prognostic groups", 
          "Luminal B", 
          "therapeutic response", 
          "wide spectrum", 
          "subtypes", 
          "cohort", 
          "luma", 
          "reproducible way", 
          "Lumb", 
          "early stage breast cancer patients", 
          "clinical samples", 
          "evidence", 
          "positive disease", 
          "predictive information", 
          "tumor subtypes", 
          "tissue", 
          "clinical behavior", 
          "gene expression analysis", 
          "large population", 
          "goal", 
          "normal breast", 
          "HER2-positive", 
          "expression analysis", 
          "real-time quantitative RT-PCR", 
          "paraffin", 
          "nodes", 
          "thousands", 
          "classification", 
          "efficacy", 
          "test", 
          "order", 
          "significant advances", 
          "unique drug sensitivity pattern", 
          "Nb", 
          "RNA", 
          "difficult disease", 
          "distinct biology"
        ], 
        "name": "Biological Breast Cancer Classification by qRT-PCR", 
        "recipient": [
          {
            "id": "https://www.grid.ac/institutes/grid.4367.6", 
            "type": "Organization"
          }, 
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.4367.6", 
              "name": "WASHINGTON UNIVERSITY", 
              "type": "Organization"
            }, 
            "familyName": "ELLIS", 
            "givenName": "MATTHEW J", 
            "id": "sg:person.012333564657.16", 
            "type": "Person"
          }, 
          {
            "member": "sg:person.012333564657.16", 
            "roleName": "PI", 
            "type": "Role"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.2689066"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2019-03-07T12:07", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_19.xml.gz", 
        "startDate": "2005-09-29T00:00:00Z", 
        "type": "MonetaryGrant", 
        "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=7658284"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2689066'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2689066'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2689066'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2689066'


     

    This table displays all metadata directly associated to this object as RDF triples.

    117 TRIPLES      19 PREDICATES      95 URIs      87 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:grant.2689066 schema:about anzsrc-for:2211
    2 schema:amount Nae63afc36a664775832a5878858f2b7e
    3 schema:description DESCRIPTION (provided by applicant): Breast cancer is a difficult disease to manage because it is comprised of a wide spectrum of tumor subtypes with different biological characteristics, therapeutic responses and clinical outcomes. A biomarker-based classification of breast cancer that effectively matches intrinsic biological characteristics with the most effective therapeutic protocol would be a significant advance. Gene expression analysis using a breast tumor "intrinsic" gene set has reproducibly identified five distinct subtypes of breast tumors: Luminal A (LumA), Luminal B (LumB), Normal Breast-like (NB), HER2-positive (HER2+) and Basal-like. Each subtype has a distinct biology and clinical behavior and evidence suggests that each has a unique drug sensitivity pattern. We have also shown that this classification identifies prognostic groups that are reproducible across different patient populations and are independent of standard clinical parameters. RNA expression profiling is the most robust and reproducible way to identify these biological subtypes and we believe that our proposed classification can be accomplished in an automated fashion without subjective interpretation. In order to generalize the clinical significance of these findings to larger populations we will develop an assay to allow classification from formalin-fixed, paraffin-embedded (FFPE) tissues so that RNA from aged blocks can be accurately profiled. Next, we will retrospectively validate our "intrinsic" gene set on uniformly treated cohorts of thousands of patients. Our goal is to develop a clinical test for these five subtypes using expression analysis by real-time quantitative RT-PCR. With the additional information that we expect to gain by profiling clinical samples from homogeneously treated patients and patients subjected to treatment randomization, we will be able to provide valuable prognostic information for patients with node negative breast cancer and predictive information for the efficacy of chemotherapy regimens for patients with node positive disease. It is our long term goal to develop a broadly applicable subtyping test for all early stage breast cancer patients.
    4 schema:endDate 2012-05-31T00:00:00Z
    5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
    6 schema:identifier N907f2e9c65114699a7243d35ba1b102f
    7 Nbe66fba182264ebd8bc567e71f464694
    8 schema:inLanguage en
    9 schema:keywords Biological Breast Cancer Classification
    10 FFPE
    11 HER2+
    12 HER2-positive
    13 Lumb
    14 Luminal B
    15 Nb
    16 RNA
    17 RNA expression
    18 additional information
    19 applicants
    20 assay
    21 automated fashion
    22 basal
    23 biological subtypes
    24 biomarkers
    25 block
    26 breast cancer
    27 breast tumors
    28 chemotherapy regimens
    29 classification
    30 clinical behavior
    31 clinical outcomes
    32 clinical samples
    33 clinical significance
    34 clinical tests
    35 cohort
    36 description
    37 different biological characteristics
    38 different patient populations
    39 difficult disease
    40 distinct biology
    41 distinct subtypes
    42 early stage breast cancer patients
    43 effective therapeutic protocols
    44 efficacy
    45 evidence
    46 expression analysis
    47 findings
    48 formalin
    49 gene expression analysis
    50 genes
    51 goal
    52 intrinsic biological characteristics
    53 large population
    54 long term goal
    55 luma
    56 luminal A
    57 negative breast cancer
    58 nodes
    59 normal breast
    60 order
    61 paraffin
    62 patients
    63 positive disease
    64 predictive information
    65 prognostic groups
    66 qRT-PCR
    67 real-time quantitative RT-PCR
    68 reproducible way
    69 significant advances
    70 standard clinical parameters
    71 subjective interpretation
    72 subtypes
    73 test
    74 therapeutic response
    75 thousands
    76 tissue
    77 treatment randomization
    78 tumor subtypes
    79 unique drug sensitivity pattern
    80 valuable prognostic information
    81 wide spectrum
    82 schema:name Biological Breast Cancer Classification by qRT-PCR
    83 schema:recipient N989e5bf2206f4a85a4120f260515f6cd
    84 sg:person.012333564657.16
    85 https://www.grid.ac/institutes/grid.4367.6
    86 schema:sameAs https://app.dimensions.ai/details/grant/grant.2689066
    87 schema:sdDatePublished 2019-03-07T12:07
    88 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    89 schema:sdPublisher N2696d1928a1f47c79f9961b42362136f
    90 schema:startDate 2005-09-29T00:00:00Z
    91 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=7658284
    92 sgo:license sg:explorer/license/
    93 sgo:sdDataset grants
    94 rdf:type schema:MonetaryGrant
    95 N2696d1928a1f47c79f9961b42362136f schema:name Springer Nature - SN SciGraph project
    96 rdf:type schema:Organization
    97 N907f2e9c65114699a7243d35ba1b102f schema:name nih_id
    98 schema:value U01CA114722
    99 rdf:type schema:PropertyValue
    100 N989e5bf2206f4a85a4120f260515f6cd schema:member sg:person.012333564657.16
    101 schema:roleName PI
    102 rdf:type schema:Role
    103 Nae63afc36a664775832a5878858f2b7e schema:currency USD
    104 schema:value 8695563
    105 rdf:type schema:MonetaryAmount
    106 Nbe66fba182264ebd8bc567e71f464694 schema:name dimensions_id
    107 schema:value 2689066
    108 rdf:type schema:PropertyValue
    109 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
    110 rdf:type schema:DefinedTerm
    111 sg:person.012333564657.16 schema:affiliation https://www.grid.ac/institutes/grid.4367.6
    112 schema:familyName ELLIS
    113 schema:givenName MATTHEW J
    114 rdf:type schema:Person
    115 https://www.grid.ac/institutes/grid.4367.6 schema:name WASHINGTON UNIVERSITY
    116 rdf:type schema:Organization
    117 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...